F

    Fulgent Genetics Inc (FLGT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $19.61
    -0.34 (-1.70%)

    Market Cap: $539.58M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    73%(29/40)
    Avg Surprise
    +81.87%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.65
    Range$-0.65 - $-0.65
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$-0.36+44.6%
    30d ago$-0.36+44.6%
    7d ago$-0.36+44.6%
    Current$-0.65
    Revenue Consensus
    $86M
    Range$86M - $86M
    1 analysts
    Dec 31, 2026
    EPS Consensus$-0.83
    Range$-0.83 - $-0.83
    1 analysts
    Revenue Consensus
    $86M
    Range$86M - $86M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.83---
    Sep 26EST
    		-$-0.65---
    Jun 26
    		$-0.88$-0.79-11.39%Miss-1357.1%
    Mar 26
    		$-0.36$-0.35-2.86%Miss-1000.0%
    Dec 25
    		$0.16$-0.06+365.78%Beat+300.0%
    Sep 25
    		$0.14$-0.22+163.64%Beat-54.8%
    Jun 25
    		$0.07N/A+138.89%Beat-53.3%
    Mar 25
    		$0.04N/A+122.22%Beat+500.0%
    Dec 24
    		$0.04N/A+110.84%Beat-85.7%
    Sep 24
    		$0.31$-0.15+306.67%Beat+179.5%
    Jun 24
    		$0.15$-0.30+150.00%Beat+287.5%
    Mar 24
    		$-0.01N/A+96.88%Beat+95.5%
    Dec 23
    		$0.28$-0.29+196.55%Beat+158.3%
    Sep 23
    		$-0.39$-0.32-21.88%Miss-750.0%
    Jun 23
    		$-0.08N/A+75.76%Beat-110.3%
    Mar 23
    		$-0.22$-0.43+48.84%Beat-104.3%
    Dec 22
    		$-0.48$-0.56+14.29%Beat-114.4%
    Sep 22
    		$0.06$0.06+0.00%Beat-98.5%
    Jun 22
    		$0.78$0.73+6.85%Beat-69.9%
    Mar 22
    		$5.08$3.86+31.61%Beat-22.1%
    Dec 21
    		$3.34$2.61+27.97%Beat-46.1%
    Sep 21
    		$3.93$3.25+20.92%Beat+88.9%
    Jun 21
    		$2.59$2.67-3.00%Miss+1423.5%
    Mar 21
    		$6.52$5.70+14.39%Beat+21833.3%
    Dec 20
    		$6.20$4.05+53.09%Beat+15400.0%
    Sep 20
    		$2.08$0.55+278.18%Beat+1385.7%
    Jun 20
    		$0.17$0.01+1600.00%Beat+183.3%
    Mar 20
    		$-0.03$0.02-250.00%Miss+50.0%
    Dec 19
    		$0.04$0.04+0.00%Beat+500.0%
    Sep 19
    		$0.14$0.03+366.67%Beat+524.2%
    Jun 19
    		$0.06$-0.03+300.00%Beat+700.0%
    Mar 19
    		$-0.06$-0.02-200.00%Miss+0.0%
    Dec 18
    		$-0.01$-0.01+0.00%Beat+83.3%
    Sep 18
    		$-0.03$-0.02-65.00%Miss-65.0%
    Jun 18
    		$-0.01N/A+66.67%Beat-150.0%
    Mar 18
    		$-0.06$-0.04-50.00%Miss-300.0%
    Dec 17
    		$-0.06$-0.01-500.00%Miss-200.0%
    Sep 17
    		$-0.02$0.02-200.00%Miss-118.2%
    Jun 17
    		$0.02$0.02+0.00%Beat-
    Mar 17
    		$0.03$0.06-50.00%Miss-
    Dec 16
    		$0.06$0.04+50.00%Beat-
    Sep 16
    		$0.11$0.09+22.22%Beat-

    Key Metrics

    Valuation
    P/E Ratio-20.86EV/EBITDA2.34x
    Price/FCF-5.29xFCF Yield-18.90%
    Profitability
    Profit Margin-26.10%Operating Margin-39.40%
    ROE-8.11%ROIC-11.27%
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio6.34xQuick Ratio6.34x
    Trading Statistics
    Beta0.91Avg Volume299.53K
    52-Week High$31.0452-Week Low$13.46

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$19.56
    SMA 20$19.10
    SMA 50$19.57
    SMA 200$20.93
    EMA 10$19.57
    EMA 20$19.41
    EMA 50$19.18
    EMA 200$19.63

    MACD

    Line: 0.15Signal: 0.04Hist: 0.11

    ADX

    ADX: 17.6+DI: 26.1-DI: 20.4

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down20.0
    PSAR$18.44

    Bollinger Bands

    Upper Band$20.42
    Lower Band$17.77
    %B Position1388%(Upper)
    Band Width0.69

    RSI (14-Day)

    Neutral
    52.7

    Momentum Oscillators

    Stoch %K67.4
    Stoch %D69.5
    Williams %R-40.6
    ROC (10d)5.7%
    Momentum1.05
    CCI (20d)72.3
    MFI (14d)50.6

    Volatility Measures

    ATR (14d)$0.67(3.4%)
    StdDev (20d)0.66
    Hist Vol40.5%(High)

    Volume Flow

    VWAP$19.68
    OBV7.1M
    AD Line738.1K
    CMF (20d)0.244

    Volume Metrics

    Avg Vol (20d)249.6K
    Vol Ratio0.8x
    VWMA (20d)$18.98

    Pivot Points

    R3$20.66
    R2$20.44
    R1$20.19
    Pivot Point$19.97
    S1$19.72
    S2$19.50
    S3$19.25

    Advanced Oscillators

    TSI5.14
    Ultimate Osc49.7
    KST-9.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$85.39M$71.14M$83.34M$84.07M$81.80M$73.46M$76.21M$71.74M$71.03M$64.48M$70.50M$84.69M
    Cost of Revenue$59.71M$49.65M$50.75M$48.56M$47.37M$45.12M$44.37M$44.97M$44.54M$42.38M$45.28M$44.84M
    Gross Profit$25.68M$21.49M$32.58M$35.51M$34.44M$28.35M$31.85M$26.77M$26.49M$22.10M$25.23M$39.84M
    Operating Expenses$61.75M$56.11M$68.82M$50.86M$54.15M$48.14M$47.98M$43.85M$45.40M$43.90M$176.35M$39.63M
    R&D$14.55M$14.18M$14.17M$13.86M$13.48M$12.39M$12.11M$11.78M$13.49M$11.43M$11.95M$10.01M
    SG&A$27.20M$27.68M$41.65M$23.34M$26.39M$25.29M$24.34M$20.95M$21.33M$21.49M$31.71M$17.50M
    Operating Income$-36,073,000$-34,622,000$-36,238,000$-15,350,000$-19,713,000$-19,795,000$-16,135,000$-17,079,000$-18,906,000$-21,798,000$-151,121,000$214,000
    Interest Income$6.40M$8.65M$6.94M$7.87M$8.09M$8.02M$8.12M$8.09M$7.71M$7.38M$6.27M$6.47M
    Interest Expense$59,000$17,000$0$0$17,000$14,000$0$1.45M$0$-249,000$0$70,000
    Income Before Tax$-29,690,000$-25,978,000$-29,274,000$-7,509,000$-21,519,000$-11,723,000$-8,037,000$-18,532,000$-11,214,000$-14,173,000$-145,196,000$6.86M
    Income Tax Expense$29,000$-704,000$-5,624,000$-683,000$-2,263,000$176,000$-1,847,000$-3,838,000$-2,124,000$-327,000$-10,862,000$20.33M
    Net Income$-29,719,000$-25,274,000$-23,650,000$-6,826,000$-19,256,000$-11,899,000$-6,190,000$-14,694,000$-9,090,000$-13,846,000$-134,334,000$-13,466,000
    EBITDA$-29,102,000$-29,502,000$-31,024,000$-10,414,000$-24,945,000$-15,466,000$-11,473,000$-22,023,000$-14,228,000$-16,328,000$-146,117,000$5.69M
    EBIT$-36,035,000$-34,612,000$-36,194,000$-15,355,000$-29,593,000$-19,727,000$-16,120,000$-26,608,000$-18,895,000$-21,807,000$-151,121,000$458,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FLGT

    Government Contracts

    Gov Obligations (TTM)
    $5.00M
    Gov Obligations / Revenue
    1.5%
    Obligations YoY
    -5.1%
    Active Awards
    5
    New Awards (TTM)
    1
    Avg Remaining Term
    2.0 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C10X25N0265Department of Veterans AffairsDepartment of Veterans Affairs$6.57MSep 30, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    FLGT | Fulgent Genetics, Inc. Common Financials - Revenue Breakdown

    This page provides a detailed financial overview of Fulgent Genetics, Inc. (FLGT), focusing on its revenue breakdown, alongside other financial data like insider trading, institutional holdings, lobbying activities, and patent grants. It also includes analyst ratings, stock forecasts, and a company profile, while indicating that specific revenue segment data is currently unavailable.

    Quiver Quantitative•8/23/26•
    Neutral

    Renaissance Technologies LLC Decreases Stock Position in Fulgent Genetics, Inc. $FLGT

    Renaissance Technologies LLC significantly reduced its stake in Fulgent Genetics, Inc. by 78.3% in Q1 2026, selling 64,864 shares and retaining 18,000 shares valued at $286,000. This divestment follows Fulgent Genetics' weaker-than-expected quarterly results, including an adjusted loss of $0.58 per share and revenue below analyst estimates. Analyst sentiment remains cautious, with an average "Hold" rating and recent downgrades.

    MarketBeat•8/20/26•
    Bearish

    Fulgent Genetics (NASDAQ:FLGT) Share Price Crosses Below Fifty Day Moving Average - Here's What Happened

    Fulgent Genetics (NASDAQ:FLGT) saw its share price drop below its 50-day moving average, trading as low as $18.96 before closing at $19.74. The company missed its quarterly earnings expectations, reporting an adjusted loss of $0.58 per share against an estimated loss of $0.46, and revenue of $85.39 million compared to a $94 million consensus. Analyst sentiment remains mixed with a consensus "Hold" rating and a price target of $27.50.

    MarketBeat•8/20/26•
    Bearish

    Fulgent Genetics, Inc. $FLGT Shares Purchased by Quantinno Capital Management LP

    Quantinno Capital Management LP significantly increased its stake in Fulgent Genetics, Inc. (NASDAQ:FLGT) by 374.7% in the first quarter, bringing its total holdings to 137,479 shares valued at $2.19 million. Institutional investors now own 48.06% of FLGT, while company insiders hold 36.18%, with recent insider sales primarily for tax obligations. Despite the increased institutional investment, analysts maintain a consensus "Hold" rating with a $27.50 price target, following the company's miss on quarterly revenue and EPS estimates and ongoing negative profitability.

    MarketBeat•8/11/26•
    Somewhat-Bearish

    Discipline and Rules-Based Execution in FLGT Response

    This article analyzes Fulgent Genetics Inc. (NASDAQ: FLGT), highlighting a near-term strong sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 98.2:1 risk-reward setup, targeting a 28.2% gain versus 0.3% risk. The article details three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis for various time horizons.

    Stock Traders Daily•8/10/26•
    Bullish

    Frequently Asked Questions About FLGT

    Does FLGT pay dividends?
    Fulgent Genetics Inc (FLGT) does not currently pay a regular dividend.
    What is FLGT's market cap?
    Fulgent Genetics Inc (FLGT) has a market capitalization of $539.58M with a current stock price of $19.61.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In